Beneficial effects of sitagliptin and metformin in non-diabetic hypertensive and dyslipidemic patients

Obesity,dyslipidemia and hypertension are major risk factors for cardiovascular disease and its associated complications. to evaluate the beneficial effects of sitagliptin and metformin in non-diabetic dyslipidemic and hypertensive patients. a prospective randomized clinical trial was conducted on 70 newly diagnosed dyslipidemic patients with bmi > 25 and blood pressure > 130/80 at outpatient clinic of medical unit-1 of sheikh medical college/hospital,rahim yar khan. they were divided in to three groups each containing 35 patients; first group served as a healthy control while second and third study groups were given tablet sitagliptin 50mg and tab metformin 850mg respectively twice a day for twelve weeks. after three months treatment with sitagliptin and metformin there was significant reduction in body weight (sitagliptin 6.5% vs metformin 7.65%) and bmi (sitagliptin 2.2% vs metformin 2.8%) with p <0.05. metformin caused a significant reduction in blood pressure with p < 0.05 (i.e. sbp 9.9% & dbp 6.4%) while sitagliptin caused a highly significant p <0.01 reduction in blood pressure (i.e. sbp 15.8% & dbp 12.2%). there was significant improvement in lipid profile with sitagliptin p<0.05. the percent reduction in value of tc,tg and ldl-c was 20.2%,13.8% and 23.7% while hdl-c value was increased 11.2% respectively. there was highly significant improvement in lipid profile with metformin p<0.01. the percent reduction in value of tc,tg and ldl-c was 27.8%,28.2% and 40.4% while hdl-c value was increased 16.8% respectively. both drugs improve cardiometabolic risk factors independently in non-diabetic patients.